DARMSTADT, Germany, October 22, 2018 /PRNewswire/ --
The information contained is not intended for distribution in the USA, Canada or the UK
ESMO Abstract # M7824 (TGF beta-trap/anti-PD-L1): 10480, 1463P, 757P, 643P, 642P, 661P, 1931P
- New data presented at the ESMO 2018 Congress include first disclosure of results for M7824 in advanced squamous cell carcinoma of the head and neck, biliary tract cancer and esophageal cancers - Updated data also being presented include non-small cell lung cancer and gastric cancer - M7824 is a bifunctional immunotherapy designed to bring together transforming growth factor-beta and anti-PD-L1 mechanisms
Merck, the vibrant science and technology company, today announced new and updated results from expansion cohorts of two ongoing M7824 Phase I clinical trials (NCT02517398 and NCT02699515) at the ESMO (European Society for Medical Oncology) 2018 Congress in Munich, October 19-23.